Noveris Health Sciences Announces Leadership Changes
Vancouver, British Columbia — March 10, 2026 — Leads & Copy — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) announced today that Joshua Bartch has resigned from his positions as director, president, and chief executive officer of the Company.
Jason Birmingham, previously appointed chief strategy officer on February 2, 2026, has been appointed to assume all three positions formerly held by Bartch.
The Company expressed its gratitude to Bartch for his service and extended wishes for his future endeavors.
Noveris Health Sciences Inc. is a biotechnology company focused on developing medications and therapies to address mental health disorders like nicotine addiction and posttraumatic stress disorder (PTSD). The company blends technology with infrastructure for drug discovery and development. The company’s team develops paths for treatment solutions in areas with unmet needs. By collaborating with specialists, the Company aims to responsibly speed up the development of medications to provide safer and more effective treatment solutions. Noveris’ approach focuses on psychedelic medicine by creating innovative compounds through its clinical trial efforts.
NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Source: TheNewswire
Share this story:
